News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SciFluor Life Sciences, LLC Presents New Preclinical Data Highlighting Lead Program as a More Potent and Selective Treatment for Partial-Onset Seizure



6/25/2013 11:16:53 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--SciFluor Life Sciences, a drug discovery and development company leveraging the transformational power of fluorine to enrich pipelines with innovative new therapeutics, today presented new preclinical data for SF0034, a novel potassium channel opener for the treatment of partial-onset seizure. Results show that SF0034 demonstrated a five-fold increase in potency, improved selectivity and a favorable pharmacological profile in a series of in vitro and in vivo preclinical models compared to ezogabine, a therapy currently approved in the U.S. and other global markets for the treatment of partial-onset seizure. These findings were presented by Scott Edwards, Ph.D., vice president, SciFluor, during a poster session held today at the 30th International Epilepsy Congress.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES